摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(3E,5E)-3,5-bis[(4-methylphenyl)methylidene]-1-prop-2-enoylpiperidin-4-one | 1009817-64-4

中文名称
——
中文别名
——
英文名称
(3E,5E)-3,5-bis[(4-methylphenyl)methylidene]-1-prop-2-enoylpiperidin-4-one
英文别名
——
(3E,5E)-3,5-bis[(4-methylphenyl)methylidene]-1-prop-2-enoylpiperidin-4-one化学式
CAS
1009817-64-4
化学式
C24H23NO2
mdl
——
分子量
357.452
InChiKey
PBKYTQAWPQYYBI-JFMUQQRKSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.4
  • 重原子数:
    27
  • 可旋转键数:
    3
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.17
  • 拓扑面积:
    37.4
  • 氢给体数:
    0
  • 氢受体数:
    2

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    (3E,5E)-3,5-bis[(4-methylphenyl)methylidene]-1-prop-2-enoylpiperidin-4-onepotassium carbonate碘甲烷 作用下, 以 四氢呋喃氯仿 为溶剂, 反应 48.0h, 生成 (3-{E},5-{E})-3,5-bis[(4-methylphenyl)methylene]-1-[3-(4-hydroximino-1-piperidyl)propanoyl]piperidin-4-one methiodide
    参考文献:
    名称:
    新型1-[3-{3,5-双(亚苄基)-4-氧代-1-哌啶基}-3-氧代丙基]-4-哌啶酮肟及相关季铵盐的设计、合成及肿瘤选择性毒性
    摘要:
    制备了一系列新型 1-[3-{3,5-双(亚苄基)-4-氧代-1-哌啶基}-3-氧代丙基]-4-哌啶酮肟3a – h和相关季铵盐4a – h作为候选抗肿瘤药物。针对肿瘤性 Ca9-22、HSC-2 和 HSC-4 细胞的评估表明,系列3和系列4中的化合物几乎在所有情况下都是有效的细胞毒素,其 CC 50值为亚微摩尔。相比之下,这些化合物对 HGF、HPLF 和 HPC 非恶性细胞的杀细胞作用较小,显示出它们的肿瘤选择性毒性。定量结构-活性关系表明,一般来说,细胞毒性效力和选择性指数随着哈米特西格玛值大小的增加而增加。此外, 3a – h对许多白血病细胞和结肠癌细胞具有细胞毒性。 4b 、 c降低CEM细胞中的线粒体膜电位, 4d诱导Ca9-22细胞中瞬时G2/M积累。五种化合物,即3 c 、 d和4c – e ,被确定为具有药物样特性的先导分子。
    DOI:
    10.3390/molecules26237132
  • 作为产物:
    参考文献:
    名称:
    新型1-[3-{3,5-双(亚苄基)-4-氧代-1-哌啶基}-3-氧代丙基]-4-哌啶酮肟及相关季铵盐的设计、合成及肿瘤选择性毒性
    摘要:
    制备了一系列新型 1-[3-{3,5-双(亚苄基)-4-氧代-1-哌啶基}-3-氧代丙基]-4-哌啶酮肟3a – h和相关季铵盐4a – h作为候选抗肿瘤药物。针对肿瘤性 Ca9-22、HSC-2 和 HSC-4 细胞的评估表明,系列3和系列4中的化合物几乎在所有情况下都是有效的细胞毒素,其 CC 50值为亚微摩尔。相比之下,这些化合物对 HGF、HPLF 和 HPC 非恶性细胞的杀细胞作用较小,显示出它们的肿瘤选择性毒性。定量结构-活性关系表明,一般来说,细胞毒性效力和选择性指数随着哈米特西格玛值大小的增加而增加。此外, 3a – h对许多白血病细胞和结肠癌细胞具有细胞毒性。 4b 、 c降低CEM细胞中的线粒体膜电位, 4d诱导Ca9-22细胞中瞬时G2/M积累。五种化合物,即3 c 、 d和4c – e ,被确定为具有药物样特性的先导分子。
    DOI:
    10.3390/molecules26237132
点击查看最新优质反应信息

文献信息

  • A facile chemo-, regio- and stereoselective synthesis and cholinesterase inhibitory activity of spirooxindole–pyrrolizine–piperidine hybrids
    作者:Yalda Kia、Hasnah Osman、Raju Suresh Kumar、Vikneswaran Murugaiyah、Alireza Basiri、Subbu Perumal、Ibrahim Abdul Razak
    DOI:10.1016/j.bmcl.2013.03.027
    日期:2013.5
    A series of novel hybrid spiro heterocycles comprising pyrrolizine, spiroxindole and piperidine moieties was synthesized chemo-, regio- and stereoselectively in good yields from 1,3-dipolar cycloaddition reaction of a series of 1-acryloyl-3,5-bisarylmethylidenepiperidin-4-ones with azomethine ylides generated in situ from 5-choloroisatin and l-proline in methanol. These cycloadducts displayed significant
    通过一系列1-丙烯酰基-3,5-双芳基亚甲基哌啶-4-的1,3-偶极环加成反应,以化学,区域和立体选择性高收率合成了一系列新的杂螺环杂环,包括吡咯嗪,螺氧并吲哚和哌啶部分具有在甲醇中由5-胆红素和1-脯氨酸原位产生的甲亚胺基亚胺的化合物。这些环加合物显示出显着的胆碱酯酶抑制活性。在筛选的化合物中,8g和8e表现出对乙酰胆碱酯酶(AChE)和丁酰胆碱酯酶(BChE)的最大抑制活性,IC 50值分别为3.33和3.13μM。
  • Method for the Inhibition of Deubiquitinating Activity
    申请人:Vivolux AB
    公开号:US20130079370A1
    公开(公告)日:2013-03-28
    A method of treating in a person a cancer tumor refractory to treatment with bortezomib or an agent sharing the apoptosis generating activity of bortezomib or any other anti-cancer drug, comprises administering to the person, in a pharmaceutically acceptable carrier, a pharmacologically effective dose of an agent selected from the group consisting of b-AP15 and other proteasome inhibitor abrogating the deubiquitinating (DUB) activity of the 19S RP DUBs.
    治疗一个对博来昔单抗或具有博来昔单抗或任何其他抗癌药物的凋亡生成活性的药物治疗无效的人的癌症肿瘤的方法,包括向该人在药学上可接受的载体中,给予从b-AP15和其他蛋白酶体抑制剂中选择的一种药物的药理有效剂量,该药物消除19S RP DUBs去泛素化(DUB)活性。
  • Ionic liquid mediated synthesis of mono- and bis-spirooxindole-hexahydropyrrolidines as cholinesterase inhibitors and their molecular docking studies
    作者:Yalda kia、Hasnah Osman、Raju Suresh Kumar、Alireza Basiri、Vikneswaran Murugaiyah
    DOI:10.1016/j.bmc.2014.01.002
    日期:2014.2
    One pot, three-component reaction of 1-acryloyl-3,5-bisarylmethylidenepiperidin-4-ones with isatin and sarcosine in molar ratios of 1: 1: 1 and 1: 2: 2 furnished to mono-and bis-spiropyrrolidine heterocyclic hybrids comprising functionalized piperidine, pyrrolidine and oxindole structural motifs. Both mono and bis-spiropyrrolidines displayed good inhibitory activity against acetylcholinesterase (AChE) with IC50 values of 2.36-9.43 mu M. For butyrylcholinesterase (BChE), mono-cycloadducts in series 8 with IC50 values of lower than 10 mu M displayed better inhibitory activities than their bis-cycloadduct analogs in series 9 with IC50 values of 7.44-19.12 mu M. The cycloadducts 9j and 8e were found to be the most potent AChE and BChE inhibitors with IC50 values of 2.35 and 3.21 mu M, respectively. Compound 9j was found to be competitive inhibitor of AChE while compound 8e was a mixed-mode inhibitor of BChE with calculated K-i values of 2.01 and 6.76 mu M, respectively. Molecular docking on Torpedo californica AChE and human BChE showed good correlation between IC50 values and free binding energy values of the synthesized compounds docked into the active site of the enzymes. (C) 2014 Elsevier Ltd. All rights reserved.
  • Synthesis and discovery of novel piperidone-grafted mono- and bis-spirooxindole-hexahydropyrrolizines as potent cholinesterase inhibitors
    作者:Yalda Kia、Hasnah Osman、Raju Suresh Kumar、Vikneswaran Murugaiyah、Alireza Basiri、Subbu Perumal、Habibah A. Wahab、Choi Sy Bing
    DOI:10.1016/j.bmc.2013.01.066
    日期:2013.4
    Three-component reaction of a series of 1-acryloyl-3,5-bisbenzylidenepiperidin-4-ones with isatin and L-proline in 1:1:1 and 1:2:2 molar ratios in methanol afforded, respectively the piperidone-grafted novel mono- and bisspiro heterocyclic hybrids comprising functionalized piperidine, pyrrolizine and oxindole ring systems in good yields. The in vitro evaluation of cholinesterase enzymes inhibitory activity of these cycloadducts disclosed that monospiripyrrolizines (8a-k), are more active with IC50 ranging from 3.36 to 20.07 mu M than either the dipolarophiles (5a-k) or bisspiropyrrolizines (9a-k). The compounds, 8i and 8e with IC50 values of 3.36 and 3.50 mu M, respectively showed the maximum inhibition of acethylcholinesterase (AChE) and butrylylcholinestrase (BuChE). Molecular modeling simulation, disclosed the binding interactions of the most active compounds to the active site residues of their respective enzymes. The docking results were in accordance with the IC50 values obtained from in vitro cholinesterase assay. (C) 2013 Elsevier Ltd. All rights reserved.
  • Cytotoxic 3,5-bis(benzylidene)piperidin-4-ones and N-acyl analogs displaying selective toxicity for malignant cells
    作者:Hari N. Pati、Umashankar Das、J. Wilson Quail、Masami Kawase、Hiroshi Sakagami、Jonathan R. Dimmock
    DOI:10.1016/j.ejmech.2007.03.010
    日期:2008.1
    A series of 3,5-bis(benzylidene)piperidin-4-ones 1, 1-acryloyl-3,5-bis(benzylidene)piperidin-4-ones 2 and adducts of 2 with sodium 2-mercaptoethanesulfonate (mesna), namely series 3, were prepared as candidate cytotoxic agents. These compounds were examined against neoplastic HSC-2, HSC-4 and HL-60 cells as well as HGF, HPC and HPLF normal cell lines and many of the compounds displayed selective toxicity for malignant cells. The CC50 values of the analogs in series 2 towards the cancer cell lines were mainly submicromolar. The relative potencies, selectivity and log P values were in the order of 2 > 1 > 3. The sulfonic acid group of a representative compound in series 3 was replaced by a thiol function to produce 4 leading to substantial increases in cytotoxic potencies and hydrophobicity indicating that the presence of a hydrophilic sulfonic acid group was disadvantageous in terms of potency. Molecular modeling suggested that the superior cytotoxicity of various members of series 1-3 over an acyclic analog 5 may have been due to the greater torsion angles theta(1) and theta(2) created between the arylidene aryl rings and the adjacent olefinic groups in series 1-3. (C) 2007 Elsevier Masson SAS. All rights reserved.
查看更多